skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

The pharmaceutical industry is ripe for the picking with a virtual smorgasbord of unpartnered product opportunities in our 2015 update. As smaller biotech and pharma companies continue to advance their pipelines to meet unmet needs they are faced with the burning question of where to allocate their limited financial resources. Should these companies continue to spend money to further develop their pipeline candidates to market or should they out-license drugs further along in development and go back to the drawing board to identify new products?

Unpartnered Products: 2015 Update

The following analysis re-examines: unpartnered branded, investigational & biologic drugs, private company pipelines with unpartnered products, public company pipelines with less than one year of cash on hand, recent licensing deals and royalties.
Unpartnered Products: 2015 Update

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: